NO20092611L - Krystallinsk faststoff Rasagilin base - Google Patents

Krystallinsk faststoff Rasagilin base

Info

Publication number
NO20092611L
NO20092611L NO20092611A NO20092611A NO20092611L NO 20092611 L NO20092611 L NO 20092611L NO 20092611 A NO20092611 A NO 20092611A NO 20092611 A NO20092611 A NO 20092611A NO 20092611 L NO20092611 L NO 20092611L
Authority
NO
Norway
Prior art keywords
rasagilin
base
crystalline solid
aminoindan
propargyl
Prior art date
Application number
NO20092611A
Other languages
English (en)
Norwegian (no)
Inventor
Tamas Koltai
Anton Frenkel
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39536623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092611(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20092611L publication Critical patent/NO20092611L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82—Purification; Separation; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
NO20092611A 2006-12-14 2009-07-08 Krystallinsk faststoff Rasagilin base NO20092611L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87501106P 2006-12-14 2006-12-14
PCT/US2007/025583 WO2008076348A1 (en) 2006-12-14 2007-12-13 Crystalline solid rasagiline base

Publications (1)

Publication Number Publication Date
NO20092611L true NO20092611L (no) 2009-09-11

Family

ID=39536623

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092611A NO20092611L (no) 2006-12-14 2009-07-08 Krystallinsk faststoff Rasagilin base

Country Status (24)

Country Link
US (4) US7750051B2 (de)
EP (1) EP2101569B1 (de)
JP (1) JP5623081B2 (de)
KR (1) KR101459744B1 (de)
CN (1) CN101557706B (de)
AT (1) ATE528989T1 (de)
AU (1) AU2007334428B2 (de)
CA (1) CA2672414A1 (de)
CY (1) CY1112511T1 (de)
DK (1) DK2101569T3 (de)
EA (1) EA016820B1 (de)
ES (1) ES2375761T3 (de)
HR (1) HRP20110980T1 (de)
IL (1) IL198985A0 (de)
MX (1) MX2009006251A (de)
NO (1) NO20092611L (de)
NZ (1) NZ577460A (de)
PL (1) PL2101569T3 (de)
PT (1) PT2101569E (de)
RS (1) RS52183B (de)
SI (1) SI2101569T1 (de)
UA (1) UA97502C2 (de)
WO (1) WO2008076348A1 (de)
ZA (1) ZA200903903B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005269416B2 (en) * 2004-07-26 2011-07-28 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
PT1848415E (pt) * 2005-02-17 2013-06-27 Teva Pharma Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
JP5738509B2 (ja) 2005-02-23 2015-06-24 テバ ファーマシューティカル インダストリーズ リミティド 内容物均一性が改善されたラサギリン製剤
CN101622225B (zh) * 2005-11-17 2015-04-15 泰华制药工业有限公司 炔丙基氨基茚分离方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
WO2007117431A2 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
CN101557706B (zh) * 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
JP2010538067A (ja) * 2007-09-05 2010-12-09 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンを使用する緑内障の治療方法
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
MX2010007601A (es) * 2008-01-11 2010-08-03 Teva Pharma Formulaciones de rasagilina, su preparacion y uso.
CN102123980B (zh) 2008-06-02 2014-05-07 基因里克斯(英国)有限公司 用于制备对映异构纯胺的方法
JP2011524353A (ja) * 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
EA201170018A1 (ru) * 2008-06-13 2011-08-30 Тева Фармасьютикал Индастриз, Лтд. Разагилин для изменения течения болезни паркинсона
CN102065853A (zh) * 2008-06-19 2011-05-18 泰华制药工业有限公司 制备和干燥固体雷沙吉兰碱的方法
EP2299993A4 (de) * 2008-06-19 2014-08-20 Teva Pharma Verfahren zum reinigen einer rasagilin-base
CN101606923B (zh) * 2008-06-20 2013-01-09 重庆医药工业研究院有限责任公司 一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法
ITMI20081406A1 (it) * 2008-07-29 2010-01-30 Dipharma Francis Srl Forma cristallina di rasagilina e procedimento per la sua preparazione
EP2358658A4 (de) 2008-11-20 2012-11-14 Reddys Lab Ltd Dr Herstellung von rasagilin und salzen davon
EP2218444A3 (de) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Rasagilinformulierung mit verzögerter Freisetzung
US8080584B2 (en) 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
CA2767592A1 (en) 2009-07-09 2011-01-13 Ratiopharm Gmbh Salts of rasagiline and pharmaceutical preparations thereof
EP2298277A1 (de) * 2009-09-09 2011-03-23 Labtec GmbH Transdermale Pflasterformulierung
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2325159A1 (de) 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Neuartige Salze von Rasagilin
EP2939669A1 (de) 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
WO2011121607A2 (en) 2010-03-29 2011-10-06 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
CN108186611A (zh) 2010-04-30 2018-06-22 帝国制药美国公司 丙炔基氨基茚满透皮组合物
RU2013108256A (ru) 2010-07-27 2014-09-10 Тева Фармасьютикал Индастриз Лтд. Дисперсии цитрата разагилина
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
WO2012129429A2 (en) 2011-03-24 2012-09-27 Teikoku Pharma Usa, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
WO2012153349A2 (en) 2011-05-04 2012-11-15 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
HK1200315A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
WO2013070526A1 (en) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
EP2610239A1 (de) 2012-01-02 2013-07-03 Dr. Reddy's Laboratories Ltd. Herstellung von Rasagilin-Hemitartrat
EP2827848B1 (de) 2012-03-21 2016-04-27 Synthon BV Stabilizierte pharmazeutische zubereitungen enthaltend salze von rasigiline
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤
US9205061B2 (en) 2012-11-02 2015-12-08 Teikoku Pharma Usa, Inc. Propynylaminoindan transdermal compositions

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252951A (en) * 1979-10-09 1981-02-24 Eli Lilly And Company Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
US4529811A (en) 1981-03-02 1985-07-16 G. D. Searle & Co. Process for isolating organic compounds and lithium salt complexes useful in said process
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
CN1031995C (zh) * 1991-01-02 1996-06-12 奥韦特有限公司 N-炔丙基-1-氨基茚满的r-对映体的制法
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US5914349A (en) * 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
FI973176L (fi) 1995-02-01 1997-07-31 Upjohn Co Selektiivisinä dopamiini-D3-ligandeina toimivia 2-aminoindaaneja
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
US5663415A (en) 1996-06-28 1997-09-02 Jame Fine Chemicals, Inc. Process for preparing antihistamine tannates
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
PT966435E (pt) 1996-12-18 2005-06-30 Yissum Res Dev Co Derivados aminoindano
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
CA2319318A1 (en) 1998-01-27 1999-07-29 Thomas N. Thomas Methods of treatment using mao-a and mao-b inhibitors such as l-deprenyl
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
IL141690A (en) 2001-02-27 2004-06-20 Isp Finetech Ltd Process for preparation of rasagiline and its salts
US6543155B2 (en) 2001-03-01 2003-04-08 National Agricultural Research Organization Freeze-dried product and process and apparatus for producing it
EP1441708B1 (de) * 2001-11-05 2009-04-08 Krele Pharmaceuticals LLC Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
US20050239054A1 (en) * 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
UA78854C2 (en) * 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same
DK1567152T3 (da) 2002-11-15 2013-10-07 Teva Pharma Anvendelse af rasagilin med riluzol til behandling af amyotroph lateral sklerose
US20040157784A1 (en) 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
ATE450535T1 (de) 2003-09-03 2009-12-15 Glaxo Group Ltd Neues verfahren zur herstellung von pleuromutilinderivaten
US7799273B2 (en) * 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
AU2005269416B2 (en) 2004-07-26 2011-07-28 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
CA2588293C (en) 2004-11-24 2013-07-02 Teva Pharmaceutical Industries Ltd. Rasagiline orally disintegrating compositions
ZA200704917B (en) 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
JP5738509B2 (ja) 2005-02-23 2015-06-24 テバ ファーマシューティカル インダストリーズ リミティド 内容物均一性が改善されたラサギリン製剤
CN101622225B (zh) * 2005-11-17 2015-04-15 泰华制药工业有限公司 炔丙基氨基茚分离方法
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP5701485B2 (ja) 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
CN101032474B (zh) 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
WO2007117431A2 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of restless legs syndrome
US7573834B2 (en) * 2006-05-31 2009-08-11 Alcatel Lucent Method and system for allocating a group bit rate among multiple bonded pairs in a communications network
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
CN101557706B (zh) 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
NZ577623A (en) 2006-12-14 2011-05-27 Teva Pharma Tannate salt of rasagiline
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
JP2010538067A (ja) 2007-09-05 2010-12-09 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンを使用する緑内障の治療方法
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
MX2010007601A (es) 2008-01-11 2010-08-03 Teva Pharma Formulaciones de rasagilina, su preparacion y uso.
EP2271612B1 (de) 2008-03-31 2016-08-10 Actavis Group PTC EHF Rasagilinmesylatpartikel und verfahren zu deren herstellung
JP2011524353A (ja) * 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
EP2299993A4 (de) 2008-06-19 2014-08-20 Teva Pharma Verfahren zum reinigen einer rasagilin-base
CN102065853A (zh) 2008-06-19 2011-05-18 泰华制药工业有限公司 制备和干燥固体雷沙吉兰碱的方法
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US8080584B2 (en) 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
CA2767592A1 (en) 2009-07-09 2011-01-13 Ratiopharm Gmbh Salts of rasagiline and pharmaceutical preparations thereof
WO2011042812A1 (en) * 2009-10-09 2011-04-14 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
EP2939669A1 (de) * 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
RU2013108256A (ru) 2010-07-27 2014-09-10 Тева Фармасьютикал Индастриз Лтд. Дисперсии цитрата разагилина
MX2013004598A (es) * 2010-10-26 2013-07-17 Teva Pharma Rasagilina enriquesida con deuterio.
AU2012323351A1 (en) * 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
HK1200315A1 (en) * 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
US20130089611A1 (en) * 2011-10-10 2013-04-11 Teva Pharmaceutical Industries, Ltd. Rasagiline citramide

Also Published As

Publication number Publication date
PT2101569E (pt) 2012-01-13
SI2101569T1 (sl) 2012-02-29
PL2101569T3 (pl) 2012-03-30
EP2101569A1 (de) 2009-09-23
US20150038744A1 (en) 2015-02-05
US20100144887A1 (en) 2010-06-10
JP2010513282A (ja) 2010-04-30
WO2008076348A1 (en) 2008-06-26
RS52183B (sr) 2012-10-31
US20100145101A1 (en) 2010-06-10
ATE528989T1 (de) 2011-11-15
UA97502C2 (ru) 2012-02-27
AU2007334428A1 (en) 2008-06-26
WO2008076348A8 (en) 2008-08-21
IL198985A0 (en) 2010-02-17
EP2101569B1 (de) 2011-10-19
CA2672414A1 (en) 2008-06-26
EP2101569A4 (de) 2009-12-02
CN101557706B (zh) 2013-08-07
MX2009006251A (es) 2009-10-12
KR20090089894A (ko) 2009-08-24
KR101459744B1 (ko) 2014-11-20
ES2375761T3 (es) 2012-03-06
CN101557706A (zh) 2009-10-14
DK2101569T3 (da) 2012-01-30
US7750051B2 (en) 2010-07-06
EA200970581A1 (ru) 2009-12-30
HRP20110980T1 (hr) 2012-02-29
US8614252B2 (en) 2013-12-24
HK1129276A1 (en) 2009-11-27
JP5623081B2 (ja) 2014-11-12
AU2007334428B2 (en) 2014-05-29
CY1112511T1 (el) 2015-12-09
ZA200903903B (en) 2010-08-25
US20080161408A1 (en) 2008-07-03
EA016820B1 (ru) 2012-07-30
NZ577460A (en) 2012-01-12

Similar Documents

Publication Publication Date Title
NO20092611L (no) Krystallinsk faststoff Rasagilin base
NO20092609L (no) Tannate salt of rasagiline
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
TW200732349A (en) Anti-OX40L antibodies and methods using same
SE0301372D0 (sv) Novel compounds
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
WO2008049116A3 (en) Substituted indoles
DK3219328T3 (da) Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
EA201170227A1 (ru) Имидазолкарбоксамиды
IL183237A0 (en) Polymorphs of memantine hydrochloride
DK1962873T3 (da) Farmaceutiske sammensætninger omfattende oxalat-reducerende bakterier
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
NO20073725L (no) CCI-779-polymorf og dens anvendelse
TW200738649A (en) Calcilytic compounds
DK1810676T3 (da) Levetiracetam formuleringer og fremgangsmåder til deres fremstilling
EA200901030A1 (ru) Антагонист хроменового рецептора s1p1
ATE552832T1 (de) Antidepressivum-propharmaka
BRPI0417205A (pt) composições farmacêuticas
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина
NO20091386L (no) Fenyloksyanilinderivater
EA200870236A1 (ru) Моногидрат римонабанта, способ его получения и фармацевтические композиции на его основе
PL1853220T5 (pl) Sposób wytwarzania pastylek zawierających NLPZ, ich kompozycje, ich zastosowanie medyczne
UA92180C2 (en) Benzimidazole thiophene compounds as plk inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application